The Division of Drug Information (DDI) is CDER's focal point for public inquiries. We serve the public by providing information on human drug products and drug product regulation by FDA.
FDA Drug Info has posted new Drug Safety Podcasts. Click on the following links to listen to the podcasts and read the transcripts
FDA approves label changes to include intestinal problems (sprue-like enteropathy) linked to blood pressure medicine olmesartan medoxomil
FDA limits usage of Nizoral (ketoconazole) oral tablets due to potentially fatal liver injury and risk of drug interactions and adrenal gland problems
FDA approves label changes for antimalarial drug mefloquine hydrochloride due to risk of serious psychiatric and nerve side effects
You can download other Drug Safety Podcasts at: FDA Drug Safety Podcasts or subscribe to the Drug Safety Podcasts channel in iTunes at: Drug Safety Podcasts.